Werner Kalow
Affiliations: | Pharmacology and Toxicology | University of Toronto, Toronto, ON, Canada |
Google:
"Werner Kalow"Mean distance: (not calculated yet)
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Aklillu E, Kalow W, Endrenyi L, et al. (2007) CYP2D6 and DRD2 genes differentially impact pharmacodynamic sensitivity and time course of prolactin response to perphenazine. Pharmacogenetics and Genomics. 17: 989-93 |
| Ozdemir V, Bertilsson L, Miura J, et al. (2007) CYP2D6 genotype in relation to perphenazine concentration and pituitary pharmacodynamic tissue sensitivity in Asians: CYP2D6-serotonin-dopamine crosstalk revisited. Pharmacogenetics and Genomics. 17: 339-47 |
| Kalow W. (2005) Pharmacogenomics: historical perspective and current status. Methods in Molecular Biology (Clifton, N.J.). 311: 3-15 |
| Kalow W. (2005) A pharmacogeneticist's look at drug effects and the drug development process: an overview. Expert Opinion On Pharmacotherapy. 6: 1299-303 |
| Ozdemir V, Kalow W, Tothfalusi L, et al. (2005) Multigenic control of drug response and regulatory decision-making in pharmacogenomics: The need for an upper-bound estimate of genetic contributions Current Pharmacogenomics. 3: 53-71 |
| Kalow W. (2004) Human pharmacogenomics: the development of a science. Human Genomics. 1: 375-80 |
| Kalow W. (2002) Pharmacogenetics and personalised medicine. Fundamental & Clinical Pharmacology. 16: 337-42 |
| Sy SK, Johnston JA, Class CF, et al. (2002) Mulitvariate cluster analysis of a human hepatic cytochrome P450 database. European Journal of Clinical Pharmacology. 58: 559-62 |
| Sy SK, Ciaccia A, Li W, et al. (2002) Modeling of human hepatic CYP3A4 enzyme kinetics, protein, and mRNA indicates deviation from log-normal distribution in CYP3A4 gene expression. European Journal of Clinical Pharmacology. 58: 357-65 |
| Ozdemir V, Kalow W, Okey AB, et al. (2001) Treatment-resistance to clozapine in association with ultrarapid CYP1A2 activity and the C-->A polymorphism in intron 1 of the CYP1A2 gene: effect of grapefruit juice and low-dose fluvoxamine. Journal of Clinical Psychopharmacology. 21: 603-7 |